SMTL ID : 7c2w.1

Crystal Structure of IRAK4 kinase in complex with a small molecule inhibitor

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 3.20 Å

Oligo State

homo-tetramer

Ligands

4 x FJ9: N-(2-morpholin-4-yl-1,3-benzoxazol-6-yl)-6-pyridin-4-yl-pyridine-2-carboxamide(Non-covalent)

FJ9.1: 14 residues within 4Å: Chain A: M.30, F.35, V.38, A.49, K.51, Y.100, V.101, Y.102, M.103, P.104, G.106, R.111, L.156, D.167 11 PLIP interactions: 11 interactions with chain A Hydrophobic interactions: A:M.30, A:V.38, A:A.49, A:Y.100, A:Y.100, A:Y.100, A:L.156 Hydrogen bonds: A:M.103, A:R.111, A:D.167 Water bridges: A:K.51 FJ9.2: 14 residues within 4Å: Chain B: M.30, V.38, A.49, K.51, V.84, Y.100, V.101, Y.102, M.103, P.104, G.106, R.111, L.156, D.167 10 PLIP interactions: 10 interactions with chain B Hydrophobic interactions: B:V.38, B:A.49, B:V.84, B:Y.100, B:Y.100, B:Y.100, B:L.156 Hydrogen bonds: B:K.51, B:M.103 Water bridges: B:D.110 FJ9.3: 16 residues within 4Å: Chain C: I.23, M.30, F.35, A.49, K.51, Y.100, V.101, Y.102, M.103, P.104, G.106, R.111, D.116, L.156, S.166, D.167 10 PLIP interactions: 10 interactions with chain C Hydrophobic interactions: C:M.30, C:A.49, C:Y.100, C:Y.100, C:Y.100, C:L.156 Hydrogen bonds: C:K.51, C:M.103, C:D.167 Water bridges: C:R.111 FJ9.4: 11 residues within 4Å: Chain D: M.30, A.49, K.51, Y.100, V.101, Y.102, M.103, P.104, G.106, L.156, D.167 9 PLIP interactions: 9 interactions with chain D Hydrophobic interactions: D:M.30, D:A.49, D:Y.100, D:Y.100, D:Y.100, D:Y.102, D:L.156 Hydrogen bonds: D:K.51, D:M.103

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Gummadi, V.R. et al., Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies. Acs Med.Chem.Lett. (2020)

Release Date

2020-11-25

Peptides

Interleukin-1 receptor-associated kinase 4: ABCD

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

C
C

D
D

Interleukin-1 receptor-associated kinase 4